Insiders and Analysts Agree These 5 Stocks Are Trading Below Value

Page 2 of 2

2. STAAR Surgical Company (NASDAQ:STAA) (EarningsAnalystsFinancials): Designs, develops, manufactures, and sells implantable lenses for the cataracts and refractive surgery. Market cap at $202.4M, most recent closing price at $5.53. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $7. This implies a potential upside of 26.58% from current levels around $5.53. Over the last six months, insiders were net buyers of 271,585 shares, which represents about 1.05% of the company’s 25.80M share float.

3. Stewart Enterprises, Inc. (NASDAQ:STEI) (EarningsAnalystsFinancials): Provides funeral and cemetery products and services in the death care industry in the United States and Puerto Rico. Market cap at $628.4M, most recent closing price at $7.36. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $9. This implies a potential upside of 20.80% from current levels around $7.45. Over the last six months, insiders were net buyers of 1,314,895 shares, which represents about 2.1% of the company’s 62.63M share float.

4. Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS) (EarningsAnalystsFinancials): Provides engineering, war fighter, security, and information technology services, solutions, and products in the United States. Market cap at $249.61M, most recent closing price at $4.41. Of the 7 analysts that have set a target price on the stock, the lowest price target stands at $5. This implies a potential upside of 15.74% from current levels around $4.32. Over the last six months, insiders were net buyers of 11,127,500 shares, which represents about 25.1% of the company’s 44.34M share float.

5. Amicus Therapeutics, Inc. (NASDAQ:FOLD) (EarningsAnalystsFinancials): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Market cap at $271.86M, most recent closing price at $5.51. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $6. This implies a potential upside of 15.38% from current levels around $5.2. Over the last six months, insiders were net buyers of 2,949,580 shares, which represents about 11.93% of the company’s 24.73M share float.

This article was originally written by Rebecca Lipman, and posted on Kapitall.

Page 2 of 2